D-2570

Phase 2Small molecule

IInventisBio Co., Ltd

D-2570 is one of 139 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

PsoriasisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Psoriatic ArthritisActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Psoriatic ArthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Preclinical

53 2

Stelara

Johnson & Johnson

Preclinical

37 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

D-2570

IInventisBio Co., Ltd

Phase 2

4 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Ulcerative Colitis

NCT07035041

Q3 2027

Phase 3Recruiting

Psoriasis

NCT07130604

Phase 3Not yet recruiting

Psoriasis

NCT07326813

Q4 2027

Phase 2Recruiting

Psoriasis

NCT07489885

Q3 2028

Phase 2Recruiting

Psoriatic Arthritis

NCT07315061

Clinical

Trials by Indication[1]

Psoriasis4 trials

Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis

Recruiting·IInventisBio Co., Ltd·Phase 3·NCT07130604·390 enrolled

Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Completed·IInventisBio Co., Ltd·Phase 2·NCT06278350·161 enrolled

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis.

Not yet recruiting·IInventisBio Co., Ltd·Phase 3·NCT07326813·477 enrolled

Show 1 more trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis

Recruiting·IInventisBio Co., Ltd·Phase 2·NCT07489885·75 enrolled

Systemic Lupus Erythematosus1 trial

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

Not yet recruiting·IInventisBio Co., Ltd·Phase 2·NCT07311200·120 enrolled

Tics1 trial

Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects

Completed·IInventisBio Co., Ltd·Phase 1·NCT07275775·100 enrolled

Ulcerative Colitis1 trial

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

Recruiting·IInventisBio Co., Ltd·Phase 2·NCT07035041·120 enrolled

Psoriatic Arthritis1 trial

A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis

Recruiting·IInventisBio Co., Ltd·Phase 2·NCT07315061·222 enrolled

1 more indication

Unspecified2 trials

Mass Balance Study of [14C] D-2570

Not yet recruiting·IInventisBio Co., Ltd·Phase 1·NCT07411742·8 enrolled

Healthy Volunteer Study

Recruiting·IInventisBio Co., Ltd·Phase 1·NCT07270783·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for D-2570. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-2570 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-2570. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InventisBio Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInventisBio Co., Ltd

D-2570

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Psoriasis4 trials

Systemic Lupus Erythematosus1 trial

Tics1 trial

Ulcerative Colitis1 trial

Psoriatic Arthritis1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News